bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.
about
axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinaseProtein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathwayTranscriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinasesChronic myeloid leukemia: reminiscences and dreamsOncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesBcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancyBCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.Murine models of acute leukemia: important tools in current pediatric leukemia research.Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.GATA-1 but not SCL induces megakaryocytic differentiation in an early myeloid lineExpression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-AblTumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids.The age incidence of chronic myeloid leukemia can be explained by a one-mutation model.Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitorsExpression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth.The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.One thousand patients with primary myelofibrosis: the mayo clinic experience.BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogeneUnresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells.Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cellsThe legacy of the Philadelphia chromosome.Treatment for chronic myelogenous leukemia: the long road to imatinibA 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.Re-evaluating the role of BCR/ABL in chronic myelogenous leukemiaRecurrent gene fusions in prostate cancerAbnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activityExpression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasiaTriptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Leukemia initiated by hemopoietic stem cells expressing the v-abl oncogene.
P2860
Q24310364-2905341B-EF51-4445-B669-F90C3966DD2FQ24311296-A2D4E3F6-4E7A-4096-AC4B-81C2B4A13EABQ24324144-5158F505-776F-4594-AD84-7FB5F319DF41Q24564193-F8F48EF7-DC69-427D-987D-70AA590A8A66Q26748769-CCFB6E90-8D03-4BBD-8EA1-133C6ACAB0E9Q26768158-B66FA08B-620B-49F0-911C-6873EE6AF117Q30175351-1EB44840-E94D-4FE1-8894-F38AAE397A3BQ30195698-D1D59A25-A11D-4945-94D1-E57F99CA8F14Q33606018-ACC461B1-DF5A-4F5E-8068-FA27535E228DQ33764518-8F8D7452-60E8-4505-9C74-B9197F693E81Q33889476-28D26253-FA1C-4CFC-9EB1-5F5F3F2B6DA7Q33938789-7CD20764-4FF0-4AE0-A747-DF679D776012Q33961815-D2A557BA-F3B4-4B28-B5E8-953C3F4FC893Q33967112-3043B2D8-6DDC-48B5-B5C2-0EBF334830BCQ34206916-545D8DB6-549D-42D5-826E-80DB602337A9Q34375891-6ADF1160-7BDC-41D2-BD61-F636E8884050Q35075559-7EB2DA2D-F410-4149-A94D-C6D17DFC8C26Q35459748-A264104E-CE1B-4B34-B942-AAE715E1E18EQ35811198-0694E718-DDE6-41C5-B22F-6E2B4DEB544AQ36262876-41C000B1-7A61-4DFE-B2ED-B87E9F3882FDQ36334327-84F85D91-7814-4B93-8637-DABBBFDC1B4FQ36363202-3F249906-8E37-43AA-8F75-05A31D1E8074Q36368162-8B687045-2C10-4D69-9B05-ED9FD97180BAQ36512816-9E5C84D5-517D-4540-8D00-134353B0EEB9Q36653547-888E42DF-9CCD-4F5A-B6BB-0F0B88DEE741Q36729655-BB7B4060-D7E0-46ED-961E-68A0B3DB6C5BQ36732643-6507CF46-59C4-4A8E-B79C-7343FBCA3457Q36739192-AADFD1EB-FEB6-4B73-AB8E-A1ABD3AF67BFQ36843769-238768E5-C5DA-4378-9D13-F24C4AA8B6AEQ36900099-98189C1F-0695-4596-9148-96E2222616F2Q36900105-AE0696E2-28AA-4FD3-9047-9E21629AE6C4Q36963802-97F32B95-D720-40A0-8ACA-3EB73F05486BQ36965464-E280A340-8947-4DAE-8423-9BBF1AF91D9CQ36997520-58710A77-494C-42B7-A722-59B1426DAD75Q37194503-E7377823-2FA4-49A0-8E3A-6C034B0B7195Q37251148-2E84382F-883E-4CD0-A119-9AB086F2AAA6Q37320065-40B81F53-58A6-4C44-A6F7-3C4288F5747EQ37369672-958DE2CE-B2A5-4A47-B4D3-5C110E1F7E9FQ37379320-0B54ABA8-2EE0-4F0A-9A25-78DF871DD050Q37409990-2FF7900A-CEBD-4F5E-9F75-4CCA1A47BCEC
P2860
bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.
description
1990 nî lūn-bûn
@nan
1990 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
bcr-abl, the hallmark of chron ...... aemopoietic neoplasms in mice.
@ast
bcr-abl, the hallmark of chron ...... aemopoietic neoplasms in mice.
@en
type
label
bcr-abl, the hallmark of chron ...... aemopoietic neoplasms in mice.
@ast
bcr-abl, the hallmark of chron ...... aemopoietic neoplasms in mice.
@en
prefLabel
bcr-abl, the hallmark of chron ...... aemopoietic neoplasms in mice.
@ast
bcr-abl, the hallmark of chron ...... aemopoietic neoplasms in mice.
@en
P2860
P1433
P1476
bcr-abl, the hallmark of chron ...... haemopoietic neoplasms in mice
@en
P2093
A G Elefanty
I K Hariharan
P2860
P304
P356
10.1002/J.1460-2075.1990.TB08212.X
P407
P50
P577
1990-04-01T00:00:00Z